Key facts
- Laminar Pharma’s last known valuation is $168.0M.
- It has raised $46.0M; the latest was Later Stage VC ($9.7M) in Nov 2024.
- Notable investors include Keiretsu Forum, OK Ventures, Dentol Capital, Alba Pérez Foundation, Horizon 2020 — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Laminar Pharma
- ·The full record, as it builds
Funding rounds
No funding rounds for Laminar Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Laminar Pharma
Operator of a biopharmaceutical company intended to focus on the discovery of membrane-lipid therapy-based drugs. The company's drugs specifically interact with and modulate the activity of key signal-transduction peripheral proteins involved in the pathogenesis of serious diseases like cancer, inflammatory or metabolic diseases, enabling physicians with a safe and efficacious therapeutic alternative.
- Sector
- Healthcare
- HQ
- Palma de Mallorca, Spain
- Founded
- 2006
- Employees
- 30
- Website
- laminarpharma.com/
- Ownership
- Privately Held (backing)
Laminar Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Laminar Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Laminar Pharma in its N-PORT filings yet. We sweep new filings monthly.